Idealp-Pharma : « hit-to-candidate » services

19 June 2008 - Services to accelerate programs from biological target to first-in-man use -
Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics, screening, early ADMET and preclinical development capabilities to speed up partner’s and client’s small molecules programs from biological target to first-in-man use...
...About Idealp-Pharma
Idealp-Pharma’s aim is to expand partner’s drug pipeline by accelerating drug discovery process from the biological target to first-in-man use. Idealp-Pharma provides a range of flexible services: including fully integrated drug discovery and preclinical development, medicinal chemistry and cheminformatics. Idealp-Pharma’s purpose-built lab covers a total of 2000 square meters. Idealp-Pharma now employs 60 staff... [PDF] Idealp-Pharma's Press Release -

Graftys BCP : FDA Approval

08/31/03 - Graftys® BCP, synthetic bone void filler, has been FDA approved for its indications in orthopaedics.
The Graftys® BCP has had EC accreditation since January 2007.
About Graftys
Graftys is a Young Innovative Company specializing in bone tissue engineering. Graftys has strong expertise in biomaterials synthesis and works in several original directions with a view to have eventually one of the widest product offers on the market... Graftys' Press Release - Communiqué de Presse de Graftys -

Cytheris : Publication of IL-7 Oncology Data in The Journal of Experimental Medicine

Paris – June 26, 2008 – Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, nonlymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S. National Cancer Institute (NCI) investigators lead by Claude Sportès, Crystal Mackall and Ronald Gress, support the potential of the IL-7 investigational product as an immunotherapy for the treatment of patients with impaired immunity due to physiologic (age), iatrogenic (chemotherapy or
transplantation) or pathologic (HIV) lymphodepletion...
... About Cytheris –
Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HCV and HIV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).
The company operates from its headquarters and laboratories in Issy-les-Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland... [PDF] Cytheris' Press Release - PDF du Communiqué de Presse de Cytheris -

MEDIT first release of a pipeline pilot component collection

05/28/2008 - MEDIT first release of a pipeline pilot component collection - MEDIT has joined others software editors in the Accelrys Independent Software Vendors (ISV) partner program.
This first release consists of three modules: MED-SuMo server, MED-Hybridise Lead discovery and MED-Hybridise Lead optimization. The modules facilitate our target based ligand generation protocol: populating a binding site with 3D fragments and generating/optimizing leads... MEDIT's Press Release -

Genewave : Launch of the First Real-Time Microarray Platform: HybLive

PALAISEAU, France, May 5, 2008 -- Genewave S.A.S. announced that it will introduce HybLive™, its fully automated microarray platform, at AMT Conference in Barcelona on May the 7th and 8th. HybLive™ combines hybridization, washing, melting and real-time fluorescence imaging in a compact benchtop package.

HybLive™ is the first open microarray platform allowing real-time measurement of the on-slide hybridization and melting of target molecules to thousands of probes simultaneously. It enables a variety of applications such as rapid verification and validation of probe design, environmental sample monitoring, multiplex on-chip melting curves determination, on-chip DNA and protein interaction studies... With its high sensitivity and excellent discriminative power, HybLive™ also enables reliable genotyping studies and even SNP discrimination using unamplified genomic DNA... Genewave's Press Release -